Influence of antecedent Glivec® therapy (imatinib mesylate) on allogeneic stem cell transplantation outcome in CML Ph+ and ALL Ph+ patients -: single-centre experience

被引：0
|
作者：
Holowiecki, J [1 ]
Kruzel, T [1 ]
Wojnar, J [1 ]
Krawczyk-Kulis, M [1 ]
Wylezol, I [1 ]
机构：
[1] L Warynski Silesian Med Acad, Katowice, Poland
来源：
BONE MARROW TRANSPLANTATION | 2004年 / 33卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S138 / S138
页数：1
相关论文
共 50 条
  • [1] Allogeneic stem cell transplantation from unrelated and related donors is effective in CML Ph+ and ALL Ph+ patients pretreated with imatinib.
    Holowiecki, J
    Kruzel, T
    Wojnar, J
    Krawczyk, M
    Skotnicki, A
    Holowiecka, B
    Kuliczkowski, K
    Hellman, A
    Wylezal, I
    Kata, D
    BLOOD, 2003, 102 (11) : 436B - 436B
  • [2] Outcome of patients with CML/Ph positive ALL who received imatinib mesylate before or after allogeneic stem cell transplant - a single-centre experience
    Chew, TK
    Ong, TC
    Tan, SM
    Sathar, J
    Chang, KM
    Purushothaman, SV
    BONE MARROW TRANSPLANTATION, 2005, 35 : S381 - S382
  • [3] Safety, tolerability and drug interactions of adjuvant imatinib mesylate (Gleevec) within the first 100 days following stem cell transplantation in patients with PH+ CML and PH+ all at high risk for recurrence
    Sheth, S
    Hicks, K
    Ippoliti, C
    Giralt, S
    Champlin, R
    Anderlini, P
    BONE MARROW TRANSPLANTATION, 2003, 31 : S44 - S44
  • [4] Allogeneic stem cell transplantation (SCT) in Ph+ CML: still a therapeutic option?
    Krieger, O.
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2010, 3 (01) : 16 - 18
  • [5] Allogeneic stem cell transplantation (SCT) in Ph+ CML: still a therapeutic option?
    Otto Krieger
    memo - Magazine of European Medical Oncology, 2010, 3 (1) : 16 - 18
  • [6] Skin changes on continued imatinib therapy in patients with Ph+ CML
    Saikia, Tapan
    Hazarika, Nandim
    Dhabhar, Boman
    BLOOD, 2007, 110 (11) : 870A - 870A
  • [7] Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia
    P Wernstedt
    M Brune
    P-O Andersson
    B Gustavsson
    D Stockelberg
    H Wadenvik
    Bone Marrow Transplantation, 2002, 30 : 971 - 973
  • [8] Aurora kinase inhibitors in the treatment of CML and Ph+ all patients resistant to imatinib
    Papayannidis, C.
    Iacobucci, I.
    Paolini, S.
    Piccaluga, P. P.
    De, Rosa F.
    Lama, B.
    Laterza, C.
    Giannoulia, P.
    Verlicchi, L.
    Chiavaroli, F.
    Ottaviani, E.
    Baccarani, M.
    Martinelli, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 45 - 46
  • [9] A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL
    Arinobu Tojo
    Kensuke Usuki
    Akio Urabe
    Yasuhiro Maeda
    Yukio Kobayashi
    Itsuro Jinnai
    Kazuma Ohyashiki
    Miki Nishimura
    Tatsuya Kawaguchi
    Hideo Tanaka
    Koichi Miyamura
    Yasushi Miyazaki
    Timothy Hughes
    Susan Branford
    Shinichiro Okamoto
    Jun Ishikawa
    Masaya Okada
    Noriko Usui
    Hiromi Tanii
    Taro Amagasaki
    Hiroko Natori
    Tomoki Naoe
    International Journal of Hematology, 2009, 89 : 679 - 688
  • [10] Impact of allogeneic haematopoietic stem cell transplantation in the outcome of Ph+ acute lymphoblastic leukaemia treated with an imatinib-containing regimen
    Costa, Luciano J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 146 (05) : 576 - 577
12345